COMP <GO>
COAG vs VIR // EV/EBITDA & P/E VALUATION
Hemab Therapeutics Holdings Inc. (NASDAQ) VS. Vir Biotechnology Inc. (NASDAQ) • 15-METRIC TALLY: COAG 1
— VIR 1
■ METRIC PARITY
LAST: $40.42 (+4.99%) • MKT CAP: $1.89B
valuation
—
LAST: $11.75 (-1.51%) • MKT CAP: $2.01B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COAG VS. VIR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COAG | VIR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -19.74% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -7.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.40 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.2 | 53.8 | +13.35 | COAG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.89B | $2.01B | -$120.9M | VIR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COAG REV | VIR REV | COAG GROSS % | VIR GROSS % | COAG FCF | VIR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $68.6M | — | 98.0% | — | -$396.6M |
| FY 2024 | — | $74.2M | — | 98.0% | — | -$453.7M |
| FY 2023 | — | $86.2M | — | — | — | -$778.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COAG // BETA —
VIR // BETA —